A heart-failure medicine reached its full dose in most Indian patients in real-world care

Heart-failure medicines only help if patients can actually reach the dose that works — side effects and frailty often get in the way. In the VERINA study, a Phase IV look at the medicine vericiguat in Indian patients with worsening heart failure and reduced ejection fraction (a heart that pumps out too little blood with each beat), doctors found high rates of patients reaching the target dose during 48 weeks of routine care, with no new safety concerns. The study, required by India's drug regulator, had no comparison group, so it cannot prove the medicine beat anything — but it answers the practical question Indian cardiologists asked: in real clinics, with real patients already on modern therapy, can people stay on it and reach the full dose? Largely, yes.

SDG 3 · Good health and well-being — Mechanism: tech innovation